Core Viewpoint - The deal aims to enhance the drugmaker's pipeline by incorporating an experimental drug targeting obesity-related comorbidities [1] Group 1 - The acquisition is focused on strengthening the company's drug development capabilities [1] - The experimental drug is specifically designed to address health issues associated with obesity [1]